Northwire Canada EditionSunday, October 18, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations

OTC · Price

Executive Summary

  • Ocumetrics Technology Corp. reported one‑month postoperative visual acuity results for all patients in Group 1 of its first‑in‑human study of the Ocumetrics Accommodating Intraocular Lens.
  • All 20+ eyes examined achieved Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25, meeting or exceeding internal safety and efficacy expectations.
  • The company will proceed with Group 2 surgeries in the coming weeks, indicating continued momentum toward later‑stage clinical development.

Key Details

  • Study Design: First‑in‑human early feasibility study; Group 1 comprised surgeries performed on Day 1 (August 2025) and Day 2 (September 2025).
  • Primary Objectives for Group 1: Confirm safety, evaluate surgical technique, assess distance vision restoration.
  • One‑Month Outcomes:
  • CDVA results: 20/32 to 20/25 across all patients.
  • Patients entered the study with significantly impaired distance vision due to cataracts; visual gains observed as early as one month post‑op.
  • Safety & Performance: No adverse events reported in the release; lens demonstrated safe implantation and strong optical performance per investigators.
  • Management Commentary:
  • Dean Burns, President & CEO, stated the results “met, and in some cases, exceeded internal expectations” and reinforce belief in the lens’s transformative potential.
  • Dr. Doyle Stulting, Chief Medical Officer, highlighted achieving 20/32 or better vision shortly after surgery as “remarkable.”
  • Next Steps: Planning for Group 2 surgeries is underway; updates expected in the coming weeks.

Notable Quotes

“We’re seeing early proof of what we set out to achieve; a next generation intraocular lens that gives a patient the vision they once had,” – Dean Burns, President & CEO.

“Achieving 20/32 or better vision this soon after surgery is remarkable… gives us great confidence as we advance to the next patient groups,” – Dr. Doyle Stulting, Chief Medical Officer.

Read the original news release →

More from Ocumetics Technology Corp.